A Brief History of CohBar, Inc. (CWBR)

CohBar, Inc. is a clinical stage biotechnology company headquartered in Menlo Park, California. The company was founded in 2007 with a focus on the research and development of mitochondria-based therapeutics.

Key Milestones:

• 2012: CohBar, Inc. was granted its first patent for mitochondrial-based therapeutics, solidifying its position as a leader in the field.
• 2015: The company went public and began trading on the NASDAQ stock exchange under the ticker symbol CWBR.
• 2017: CohBar, Inc. entered into a collaboration agreement with a major pharmaceutical company to advance its lead drug candidate into clinical trials.
• 2019: The company announced positive results from its Phase 1b clinical trial, demonstrating the safety and efficacy of its mitochondria-based therapeutic.

Today, CohBar, Inc. continues to innovate in the field of mitochondrial research, with a pipeline of potential therapies for a range of age-related diseases and conditions.

Who Owns CohBar, Inc. (CWBR)

CohBar, Inc. (CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria-based therapeutics. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol CWBR. As of the most recent data available, the ownership of CohBar, Inc. is as follows:

• Institutional Investors: Institutional investors own a significant portion of CohBar, Inc. These include mutual funds, hedge funds, and other institutional investment firms. These investors often hold large stakes in the company and have the power to influence its strategic direction.
• Insiders: Insiders of CohBar, Inc. include members of the company's management team, board of directors, and other key employees. These individuals may own shares of the company's stock and are required to disclose their ownership and trading activities to the Securities and Exchange Commission (SEC).
• Public Shareholders: Public shareholders, which include individual retail investors, also own a portion of CohBar, Inc. These shareholders buy and sell shares of the company's stock on the open market through brokerage accounts.

Overall, the ownership structure of CohBar, Inc. is diverse, with institutional investors, insiders, and public shareholders all playing a role in the ownership of the company.

CohBar, Inc. (CWBR) Mission Statement

CohBar, Inc. is a clinical stage biotechnology company focused on the research and development of novel mitochondria-based therapeutics. Our mission is to discover, develop, and commercialize innovative treatments for diseases associated with aging, such as metabolic disorders, cardiovascular diseases, and cancer.

At CohBar, we are committed to advancing the field of mitochondrial science to create transformative medicines that can improve the lives of patients worldwide. Our proprietary technology platform allows us to identify and develop peptides that target specific pathways in the mitochondria, offering a unique approach to addressing age-related diseases.

• Innovation: We are dedicated to pushing the boundaries of scientific discovery and developing groundbreaking therapies that have the potential to change the standard of care.
• Collaboration: We work closely with leading research institutions, healthcare professionals, and industry partners to leverage expertise and resources in pursuit of our shared goals.
• Integrity: We uphold the highest ethical standards in all aspects of our business, from research and development to corporate governance and patient care.

By staying true to our mission and values, CohBar is poised to make a meaningful impact on the healthcare landscape and improve outcomes for patients with age-related diseases.

How CohBar, Inc. (CWBR) Works

CohBar, Inc. is a clinical stage biotechnology company that focuses on the research and development of mitochondrial-derived peptides as potential therapeutics for various diseases. The company's proprietary technology platform enables the discovery of new peptides that regulate key processes in multiple tissues.

CohBar's research and development efforts are centered around identifying peptides that have the potential to address significant unmet medical needs. These peptides are designed to target specific receptors and signaling pathways in the body to modulate cellular functions and restore balance in diseased tissues.

The company collaborates with academic institutions, research organizations, and industry partners to advance its peptide pipeline. Through strategic partnerships, CohBar is able to leverage expertise and resources to accelerate the development of its therapeutic candidates.

CohBar's pipeline includes peptides for the treatment of metabolic disorders, cardiovascular diseases, fibrotic diseases, and cancer. The company's lead candidate, CB4211, is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and obesity.

• Metabolic Disorders: CohBar is researching peptides that target metabolic pathways to improve glucose and lipid metabolism.
• Cardiovascular Diseases: The company is developing peptides that may reduce inflammation and improve cardiovascular function.
• Fibrotic Diseases: CohBar is investigating peptides that could inhibit fibrosis and promote tissue regeneration.
• Cancer: The company is exploring peptides that have the potential to inhibit tumor growth and metastasis.

Here are some key ways in which CohBar generates revenue:

• Partnerships and collaborations: CohBar often enters into partnerships with pharmaceutical companies to co-develop and commercialize its pipeline of drug candidates. These partnerships typically involve upfront payments, milestone payments, and royalties on future sales.
• Licensing agreements: CohBar may also license its technology to other companies for use in specific disease indications. This can provide the company with upfront licensing fees as well as future royalties.
• Grant funding: CohBar has received grant funding from organizations such as the National Institutes of Health (NIH) to support its research efforts. This funding can help offset some of the costs associated with drug development.
• Investor funding: CohBar may raise capital through equity offerings or other financing arrangements to support its research and development activities. This can include private placements, public offerings, and strategic investments from venture capital firms.
• Product sales: While CohBar does not currently have any products on the market, the company's long-term goal is to advance its drug candidates through clinical trials and ultimately bring them to market. Revenue from product sales would be a major source of income for the company in the future.